(PTO-1449)	FILING DATE June 3, 2005	GROUP 1634	· · · · · · · · · · · · · · · · · · ·
DEC 2 6 2007	APPLICANT FAN, Jian-Bing		
INFORMATION DISCLOSURE OF CITATION IN AN APPLICATION	ATTY. DOCKET NO. 067234-0130	SERIAL NO. 10/537,204	

	U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	_	ocument Number per-Kind Code2 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/F.L./	1.	us	HI1531	05-07-1996	Blumentals	
20000	2.	US	4,200,110	04-29-1980	Peterson et al.	
X00000	3.	US	4,499,052	02-12-1985	Fulwyler	
000000	4.	US	4,582,789	04-15-1986	Sheldon	
00000	5.	US	4,682,895	07-28-1987	Costello	
	6.	us	4,683,195	07-28-1987	Mullis et al.	
	7.	us	4,683,202	07-28-1987	Mullis	
	8.	us	4,687,732	08-18-1987	Ward	
	9.	us	4,751,177	01-14-1988	Stabinsky	
8888	10.	us	4,785,814	11-22-1988	Kane	
	11.	us	4,822,746	04-18-1989	Walt	
	12.	us	4,824,789	04-25-1989	Yafuso et al.	
	13.	us	4,876,187	10-24-1989	Duck et al.	9
	14.	us	4,882,269	12-11-1986	Schneider et al.	
90	15.	us	4,883,750	11-12-1989	Whiteley et al.	
	16.	us	4,921,805	05-01-1990	Gebeyehu et al.	
8	17.	us	4,988,617	01-29-1991	Landeregren et al.	
8	18.	us	4,999,306	03-12-1991	Yafuso et al.	
***************************************	19.	us	5,002,867	03-26-1991	Macevicz	
	20.	US	5,011,769	04-30-1991	Duck et al.	
0000000	21.	US	5,028,545	07-02-1991	Soini	
0000	22.	US	5,104,791	04-14-1992	Abbott	
	23.	US	5,105,305	04-14-1992	Betzig et al.	
	24.	us	5,114,864	05-19-1992	Walt	
	25.	us	5,132,242	07-21-1992	Cheung	
	26.	us	5,143,853	09-01-1992	Walt	
X	27.	us	5,175,082	12-29-1992	Jeffreys	
	28.	US	5,185,243	02-09-1993	Ullman et al.	
V	29.	US	5,194,300	03-16-1993	Cheung	

EXAMINER	DATE CONSIDERED
/Frank Lu/	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*** This reference is not attached. Will be provided under separate cover.

02/16/2010

SHEET 2 OF 11 SERIAL NO. INFORMATION DISCLOSURE ATTY, DOCKET NO. 10/537,204 067234-0130 CITATION IN AN APPLICATION **APPLICANT** FAN, Jian-Bing **GROUP** FILING DATE (PTO-1449) June 3, 2005 1634 US 5.202.231 04-13-1993 Drmanac et al. 30. /F.L./ 31. US 5,244,636 09-14-1993 Walt et al. 32. ŪS 5,244,813 09-14-1993 Walt et al. Walt et al. 33. US | 5.250.264 10-05-1993 Walt 34. US 5,252,494 10-12-1993 35. US 5,254,477 10-19-1993 Walt et al. Walt et al. 36. US 5,298,741 03-29-1994 04-12-1994 Cheeseman 37. US 5.302.509 38. 06-14-1994 Walt et al. US 5,320,814 39. US 5,357,590 10-18-1994 Auracher 40. 01-10-1995 Sutton et al. US 5.380.489 04-04-1995 Walder et al. 41. US 5,403,711 US 5,435,724 04-04-1995 Goodman et al. 42. 43. US 5.445.934 08-29-1995 Fodor et al. 44. US 5,474,895 12-12-1995 Ishii et al. 45. US 5,481,629 01-02-1996 Tabuchi 46. us 5.484.798 02-27-1996 Gerdt et al. 47. US 5,494,810 02-27-1996 Barany et al. 48. US 5,496,997 03-05-1996 Pope 49. 5.503,980 04-02-1996 Cantor US Walt et al. 50. US 5,512,490 04-30-1996 Ekins et al. 51. US 5.516.635 05-14-1996 Whiteley et al. 52. US 5,521,065 05-28-1996 06-11-1996 Drmanac et al. 53. US 5,525,464 US 07-30-1996 Dahlberg et al. 54. 5,541,311 55. US 09-10-1996 Kacian et al. 5,554,516 Still et al. 56. US 5,556,324 10-15-1996 57. US 5,567,587 10-22-1996 Kohne 58. US 5.573.907 11-12-1996 Carririno et al. 59. US 5,573,909 11-12-1996 Singer et al. 60. US 5,575,849 11-19-1996 Honda et al. 61. Bhatnagar et al. US 5.593.840 01-4-1997 62. Brennar US 5,604,097 02-18-1997 **EXAMINER** DATE CONSIDERED

/Frank Lu/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

02/16/2010

SHEET 3 OF 11 ATTY, DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE 067234-0130 10/537.204 CITATION IN AN **APPLICATION APPLICANT** FAN, Jian-Bing **FILING DATE GROUP** (PTO-1449) June 3, 2005 1634 Dahlberg et al. US 5,614,402 03-25-1997 63. /F.L./ 64. US 5,632,957 05-27-1997 Heller et al. 65. ับร 5,633,972 05-27-1997 Walt et al. Dower et al. 66. US 5.639.603 06-17-1997 08-12-1997 Seifert et al. 67. US 5,656,241 68. US 5,660,988 08-26-1997 Duck et al. Nikiforov et al. 69. US 5,679,524 10-21-1997 Urdea et al. 70. US 5.681.697 10-28-1997 71. 11-25-1997 Pinkel et al. US 5,690,894 Drmanac et al. 72. US 5,695,940 12-09-1997 Ohkubo 73. US 5.719.029 02-17-1998 74: 04-28-1998 Fodor et al. US 5,744,305 75. US 06-09-1998 **Brenner** 5,763,175 76. US 5,780,231 07-14-1998 Brenner 77. US 5,795,714 08-18-1998 Cantor et al. 78. US 09-01-1998 Fodor et al. 5,800,992 79. US 5,804,376 09-08-1998 Braxton et al. 80. US 5,814,524 10-29-1998 Walt Monforte et al. 81. US 5,830,655 11-03-1998 82. 11-03-1998 US 5.830.711 Barany et al. 83. US 5,840,256 11-24-1998 Demers et al. 84 US 5,843,669 12-01-1998 Kaiser et al. US 12-08-1998 Brow et al. 85. 5.846.717 86. 12-29-1998 US 5,853,989 **Jeffreys** 87. US 5.854.033 12-29-1998 Lizardi 88. US 5,854,684 12-29-1998 Stabile et al. 89. US 5,856,083 01-05-1999 Chelsky et al. 90. US 5,858,732 01-12-1999 Solomon et al. 01-29-1999 91. US 5.863.708 Zanzucchi et al. 92. US 5,866,321 02-02-1999 Matsue et al. 93. US 5.871,928 02-16-1999 Fodor et al. 94 US 5.876.924 03-02-1999 Zhang et al. 03-30-1999 95. US 5,888,723 Sutton et al. **EXAMINER DATE CONSIDERED**

/Frank Lu/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

SHEET 4 OF 11 SERIAL NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE 10/537,204 067234-0130 CITATION IN AN **APPLICATION** APPLICANT FAN, Jian-Bing **GROUP** FILING DATE (PTO-1449) June 3, 2005 1634 05-04-1999 Lough et al. 5.900,481 96. US | /F.L./ 97. US 5.935,793 08-10-1999 Wong, et al. 98. US 5,942,391 08-24-1999 Zhang et al. US 5,952,174 09-14-1999 Nikiforov et al. 99. Mitsuhashi 100. US 5,976,797 11-02-1999 11-30-1999 Bergeron et al. 101. US 5,994,066 12-07-1999 Akhavan-Tafti 102. US 5,998,175 US 6.001,564 12-14-1999 Bergeron et al. 103. 01-11-2000 Lipshulz et al. 6,013,440 104. US 01-11-2000 Akhavan-Tafti 105. US 6,013,456 Morris, et al. 6.017.738 01-25-2000 106. US 02-08-2000 Walt et al. US 6.023,540 107. 108. US 6,045,996 04-04-2000 Cronin, et al. 04-18-2000 Sosnowski et al. 6.051.380 109. US 04-25-2000 Barany et al. 110. US 6.054,564 <u>111.</u> ŪS 6,060,245 05-09-2000 Sorge et al. 07-04-2000 Kelly et al. 112. US 6,083,753 US 6.096,496 08-01-2000 Frankel 113. US 6,096,496 08-01-2000 Frankel et al. 114. 115. US 6,110,678 08-29-2000 Welsburg et al. 09-26-2000 Fodor, et al. 116. US 6,124,102 117. ÜS 6,143,495 11-07-2000 Lizardi et al. Brenner et al. 01-09-2001 118. US 6,172,218 02-06-2001 Lizardi US 6,183,960 119. 120. US 6,197,506 03-06-2001 Fodor, et al. Walt et al. us l 6,200,737 03-13-2001 121. 04-03-2001 Lizardi 122. US 6,210,884 Mahtani US 6,221,603 04-24-2001 123. Uematsu, et al. 124. US 6,225,064 05-01-2001 05-04-2001 Pirrung et al. 125. US 6,225,625 126. US 6,251,639 06-26-2001 Kurn ŪS 6,261,776 07-17-2001 Pirrung et al. 127. US 6.266,459 07-24-2001 Walt et al. 128. DATE CONSIDERED **EXAMINER**

02/16/2010

/Frank Lu/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

I	NFOF	CITA	ATIC	N DISCLOS ON IN AN CATION	URE	ATTY. DOCKET NO. 067234-0130		IAL NO. 1537,204
						APPLICANT FAN, Jian-Bing		
(PTO-1449)					FILING DATE June 3, 2005	GR0 16 :		
/F.l	/	129.	US	6,268,148	07-31-2001	Barany et al.		
****		130.	US	6,274,323	08-14-2001	Bruchez et al.		<u>-</u>
		131.	US	6,280,935	08-28-2001	Macevicz		
		132.	us	6,284,465	09-04-2001	Wolber	_	
8		133.	US	6,291,166	09-18-2001	Gerdes et al.	****	
8000		134.	US	6,291,183	09-18-2001	Pirrung et al.		
***************************************		135.	us	6,306,643	10-23-2001	Gentalen et al.	·	
		136.	US	6,316,229	11-13-2001	Lizardi et al.		,
		137.	US	6,327,410	12-04-2001	Walt et al.		
		138.	US	6,331,393	12-18-2001	Laird et al.		
		139.	us	6,342,389	01-29-2002	Cubicciotti		
		140.	US	6,355,431	02-12-2002	Chee et al.		
		141.	US	6,372,813	04-16-2002	Johnson et al.		
80000		142.	US	6,429,027	08-06-2002	Chee et al.		
		143.	ÜS	6,534,293	03-18-2003	Barany et al.		
8		144.	US	6,544,732	04-08-2003	Chee et al.		
		145.	ŪS	6,812,005	11-02-2004	Fan et al.	***	· · · · · · · · · · · · · · · · · · ·
		146.	US	6,858,394	02-22-2005	Chee et al.		· · · · · · · · · · · · · · · · · · ·
		147.	US	6,942,968	09-13-2005	Dickinson et al.		
		148.	US	7,033,754	12-22-2000	Chee et al.	,	
		149.	us	7,060,431	06-13-2006	Chee et al.		
		150.	US	7,115,884	10-03-2006	Walt et al.		
		151.	US	09/189,543	03-01-2001	Chee		
		152.	US	09/500,555	02-09-2000	Stuelpnagel		
		153.	US	09/606,369	06-28-2000	Stuelpnagel		
		154.	US	2001/0029049	10-11-2001	Walt	···············	
		155.	US	2002/0039728	04-04-2002	Kain		
	000000	156.	US	2002/0051971	05-02-2002	Stuelpnagel		
		157.	US	2002/0064779	05-30-2002	Landergren		
		158.	US	2002/0137056	09-26-2002	Olek et al.		
		159.	US	2002/0150921	11-09-2001	Barany et al.		
		160.	US	2002/0168645	11-14-2002	Taylor		
	/	161.	US	2002/0177141	11-28-2002	Chee et al.		
	EXAMINER /Frank Lu/						DATE CONSID	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*** This reference is not attached. Will be provided under separate cover.

INFO:	CITA	ATIC	N DISCLOS ON IN AN CATION	URE	ATTY. DOCKET NO. 067234-0130		(1537,2)		
					APPLICANT FAN, Jian-Bing				
	(I	PTO-	-1449)		FILING DATE June 3, 2005	GR0 16	OUP 34		
/F.L./	162.	US	2003/0027126	02-06-2003	Walt				
8	163.	US	2003/0108900	06-12-2003	Oliphant et al.				
	164.	us	2003/0122612	09-05-2002	Walt				
8	165.	US	2003/0211489	11-13-2003	Shen et al.				
	166.	us	2004/0101835	06-12-2004	Willis et al.				
V	167.	US	2004/0137498	07-15-1004	Fan et al.				
					ATENT DOCUMENTS			T	lation
EXAMINER'S INITIALS	CITE NO.		ign Patent Document by Codes -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	B	F	Pages, columns, Lines Where Relevant Figures Appear	Yes	nslation No
/F.L./	168.	EP 0	269 764	06-08-1988	Molecular Biosystems, Inc.	+			
/ ! » E ·/	169.	EP 0	392 546	10-17-1990	Drmanac et al.				· · · · ·
- 8	170.	EP 0	478 319	04-10-1992	Tokyo Shibaura Electric Co.				
	171.	EP 0	723 146	07-24-1996	SRI International				
8	172.	EP 0	799 897	10-08-1998	Affymetrix				
8	173.	GB 2	2156074	10-02-1985	Palva, et al.				
	174.	wo	89/09835	10-19-1989	Orgel				*****
8	175.	wo	89/11101	11-16-1989	Dynal, A.S.				
	176.	wo	89/12696	12-28-1998	Richards, et al.				
	177.	wo	90/01069	02-08-1990	Segev			· · · · · · · · · · · · · · · · · · ·	
	178.	wo	90/01564	02-22-1990	Microprobe Corp.				
8	179.	wo	91/06678	05-16-1991	Tsien & Ross				
	180.	wo	91/17442	11-14-1991	Urdea, Michael	_			
	181.	wo	93/02360	02-04-1993	Transmed Biotech, Inc.				
	182.	wo	93/25563	12-23-1993	City of Hope				
	183.	wo	94/02515	02-03-1994	Bunsen Rush Laboratories				
	184.	wo	95/16918	06-22-1995	Combichem Inc.				
	185.	wo	95/21271	08-10-1995	Molecular Tool Inc.				
	186.	wo	96/03212	02-08-1996	Brenner				
4	187.	wo	96/17958	06-13-1996	Pinkey, et al.				
W	188.	wo	96/30392	10-03-1996	Ciba Geigy AG, et al.				
		EXAM	MINER /Frank I	_u/	DATE	CONSID	ERED (2/16/20	10

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.

1634

INFORMATION DISCLOSURE ATTY. DOCKET NO. SERIAL NO. 067234-0130 10/537,204 CITATION IN AN **APPLICATION APPLICANT** FAN, Jian-Bing FILING DATE **GROUP** (PTO-1449)

June 3, 2005

189. WO 97/14028 O4-17-1997 Luminex Corp. 190. WO 97/31256 O8-28-1997 Cornell Research Foundation 191. WO 97/40385 10-30-1997 Seul, Michael 192. WO 97/45559 12-04-1997 Cornell Research Foundation 193. WO 97/46704 12-11-1997 Albrecht et al. 194. WO 98/13523 O4-02-1998 Pryosequencing AB 195. WO 98/31836 O7-23-1998 Hyseq 196. WO 98/37230 O8-27-1998 Todd 197. WO 98/40726 O9-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 O4-15-1999 Trustees of Tufts College 202. WO 99/39001 O8-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Amersham Pharmacia 205. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 O1-27-2000 Board of Regents, University of Texas	
190. WO 97/31256	
192. WO 97/45559 12-04-1997 Cornell Research Foundation 193. WO 97/46704 12-11-1997 Albrecht et al. 194. WO 98/13523 04-02-1998 Pryosequencing AB 195. WO 98/31836 07-23-1998 Hyseq 196. WO 98/37230 08-27-1998 Todd 197. WO 98/40726 09-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Bioarray Solutions LLC 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 O4-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
193. WO 97/46704 12-11-1997 Albrecht et al. 194. WO 98/13523 04-02-1998 Pryosequencing AB 195. WO 98/31836 07-23-1998 Hyseq 196. WO 98/37230 08-27-1998 Todd 197. WO 98/40726 09-17-1998 Trustees of Tufts College 198. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc.	
194. WO 98/13523 04-02-1998 Pryosequencing AB 195. WO 98/31836 07-23-1998 Hyseq 196. WO 98/37230 08-27-1998 Todd 197. WO 98/40726 09-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
195. WO 98/31836 07-23-1998 Hyseq 196. WO 98/37230 08-27-1998 Todd 197. WO 98/40726 09-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
196. WO 98/37230 O8-27-1998 Todd 197. WO 98/40726 O9-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 O4-15-1999 Trustees of Tufts College 202. WO 99/39001 O8-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 O1-27-2000 Board of Regents, University of Texas	
197. WO 98/40726 09-17-1998 Trustees of Tufts College 198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
198. WO 98/50782 11-12-1998 Trustees of Tufts College 199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
199. WO 98/53093 11-26-1998 Bioarray Solutions LLC 200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
200. WO 98/53300 11-26-1998 Lynx Therapeuctics, Inc. 201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
201. WO 99/18434 04-15-1999 Trustees of Tufts College 202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
202. WO 99/39001 08-05-1999 Amersham Pharmacia, Biotech AB 203. WO 99/53102 10-21-2001 Tayloer, 204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
Biotech AB	
204. WO 99/60170 11-25-1999 Hyseq, Inc. 205. WO 99/64867 12-16-1999 Amersham Pharmacia 206. WO 99/67414 12-29-1999 Galaxo Group Limited 207. WO 99/67641 12-29-1999 Illumina, Inc. 208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
205. WO 99/64867 12-16-1999 Amersham Pharmacia	
206. WO 99/67414 12-29-1999 Galaxo Group Limited	
207. WO 99/67641 12-29-1999 Illumina, Inc.	
208. WO 00/04372 01-27-2000 Board of Regents, University of Texas	
of Texas	
209. WO 00/13004 03-09-2000 Trustees of Tufts College	
210. WO 00/16101 03-23-2000 Trustees of Tufts College	
211. WO 00/39587 07-06-2000 Illumina, Inc.	
212. WO 00/47996 08-17-2000 Illumina, Inc.	
213. WO 00/48000 08-17-2000 Illumina, Inc.	
214. WO 00/58516 10-05-2000 Whitehead Institute	
215. WO 69/60332 10 12 2000 Trustoes of Tufts Collogo	000000000000000000000000000000000000000
/F.L./ 216. WO 00/63437 10-26-2000 Illumina, Inc.	
217. WO 00/71243 11-30-2000 Illumina, Inc.	
218. WO 00/71992 11-30-2000 Illumina, Inc.	
219. WO 00/71995 11-30-2000 Illumina, Inc.	

r			
ı	EXAMINER	DATE CONSIDERED	00/46/0040
ľ	/Frank Lu/		02/16/2010
-	/Fidik Lu/		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This reference is not attached. Will be provided under separate cover.

INFO	CITA	TION DISCLOS ATION IN AN PLICATION	URE	ATTY. DOCKET NO. 067234-0130	SERIAL 1 10/537		
				APPLICANT FAN, Jian-Bing		•	
	(1	PTO-1449)		FILING DATE June 3, 2005	GROUP 1634		
/F.L./	220.	WO 00/75373	12-14-2000	Illumina, Inc.			
	221.	WO 01/06012	01-25-2001	Englert, David			_
	222.	WO 01/20035	03-22-2001	Polizzi et al.			
	223.	WO 01/57269	08-09-2001	Fan			
	224.	WO 02/57491	07-25-2002	Willis			
	225.	WO 02/61143	08-08-2002	Brown, et al.			
			<u> </u>	nor, Title, Date, Pertinent Pages, Etc.)		(hanta annoning	
EXAMINER'S INITIALS		include name of the author (in journal, serial, symposium, cat published.	CAPITAL LETTER alog, etc.), date, pa	RS), title of the article (when appropria age(s), volume-issue number(s), publi	te), title of the item isher, city and/or co	(book, magazine, juntry where	
/F.L./	226.	1	ABRAMSON et al., "Nucleic acid amplification technologies," <u>Current Opinion in</u> <u>Biotechnology</u> 4:41-47 (1993).				`
/F.L./	227.	scanning of mouse liv	AKAMA et al., "Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status," <u>Cancer Res.</u> 57:3294-3299 (1997).				
***************************************	228.			otein Coupling Techniques	for Biomedica	al Sciences,	000000000000000000000000000000000000000
		Grove's Dictionaries,	<u> </u>				
	229.			dium of Methods from Cur			000000000000000000000000000000000000000
		Biology , Short Protocols in Molecular Biology, 2nd Ed., John Wiley & Sons, New York, (1992).					
/F.L./	230.	Acids Res. 26:5073-5	BANER et al., "Signal amplification of padlock probes by rolling circle replication," <u>Nuc.</u> Acids Res. 26:5073-5078 (1998).				
0000000000	231.		BARANY, "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," Proc. Natl. Acad. Sci. USA 88:189-193 (1991).				
000000000000000000000000000000000000000	232.	BAYLIN and HERMAN, "DNA hypermethylation in tumorigenesis: epigenetics joins genetics." Trends Genet. 16:168-174 (2000).					
	233.	BESTOR, "Gene silencing. Methylation meets acetylation," Nature 393:311-312 (1998).					
	234.	CORDER et al., "Gene dose of apolipoprotein E type 4 allele and the risk of alzheimer's disease in late onset families," Science 261:921-923(1993).					
100000000000000000000000000000000000000	235.	COSTELLO et al., "Al	COSTELLO et al., "Aberrant CpG-island methylation has non-random and tumour-type specific patterns," Nat. Genet. 24:132-138 (2000).				
200000000000000000000000000000000000000	236.	1	t syndrome:	a surprising result of muta	tion in MECP	2," <u>Hum. Mol.</u>	
V	237.	DRMANAC et al., "Se method," Genomics 4		megabase plus DNA by hy 89).	/bridization: th	neory of the	

EXAMINER	/Example Lay/	DATE CONSIDERED
	/Frank Lu/	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*** This reference is not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 067234-0130	SERIAL NO. 10/537,204
	APPLICANT FAN, Jian-Bing	
(PTO-1449)	FILING DATE June 3, 2005	GROUP 1634

/F.L./	238.	FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," <u>Nucleic Acids Res.</u> 22:695-696 (1994).	
000000000000000000000000000000000000000	239.	FROMMER et al., "A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands," Proc. Natl. Acad. Sci. USA 89:1827-1831 (1992).	
200000000000000000000000000000000000000	240.	GOLUB et al., "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," <u>Science</u> 286:531-537 (1999).	
000000000000000000000000000000000000000	241.	GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE)," <u>Nucleic Acids</u> <u>Res.</u> 25:2529-2531 (1997).	
	242.	GOTO, "Regulation of X-chromosome inactivation in development in mice and humans," Microbiol. Mol. Biol. Rev. 62:362-378 (1998).	
	243.	HERMAN et al., "Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers," <u>Cancer Res.</u> 55:4525-4530 (1995).	
000000000000000000000000000000000000000	244.	HERMAN, et al., "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands," Proc. Natl. Acad. Sci. USA 93:9821-9826 (1996).	,
	245.	HERMANSON, <i>Bioconjugate Techniques</i> Academic Press, San Diego, CA, pp. 640-643 (1996).	
2000000	246.	HUANG et al., "Methylation profiling of CpG islands in human breast cancer cells," <u>Hum Mol. Genet.</u> 8:459-470 (1999).	
00000	247.	ISSA, et al., "Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon," Nat. Genet. 7:536-540 (1994).	
	248.	JONES and LAIRD, "Cancer epigenetics comes of age." Nat. Genet. 21:163-167 (1999).	
***************************************	249.	KAWAI, et al., "Comparison of DNA methylation patterns among mouse cell lines by restriction landmark genomic scanning." Mol. Cell. Biol. 14:7421-7427 (1994).	
200000000000000000000000000000000000000	250.	KOSTER et al., "A strategy for rapid and efficient DNA sequencing by mass spectrometry," Nature Biotechnology 14:1123-1128 (1996).	
0,0000000000000000000000000000000000000	251.	KUMAR, "Rett and ICF syndromes: methylation moves into medicine," <u>J. Biosci.</u> 25:213-214 (2000).	
University of the Control of the Con	252.	KUPPUSWAMY et al., "Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes," Proc. Natl. Acad Sci. USA 88:1143-1147 (1991).	
V	253.	LIZARDI et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," Nat. Genet. 19:225-232 (1998).	

EXAMINER	DATE CONSIDERED
/Frank Lu/	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*** This reference is not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 067234-0130	SERIAL NO. 10/537,204
	APPLICANT FAN, Jian-Bing	
(PTO-1449)	FILING DATE June 3, 2005	GROUP 1634

	/F.L./	254.	LOCKHART and WINZELER, "Genomics, gene expression and DNA arrays," Nature, 405:827-836 (2000).	
	000000000000000000000000000000000000000	255	NEWTON, PGR Essential Date, J.W. Wiley & Sone, New York (1995).**	000000000000000000000000000000000000000
	/F.L./	256.	NICKERSON, "Gene probe assays and their detection," <u>Current Opinion in</u> <u>Biotechnology</u> 4:48-51 (1993).	
	/F.L./	257.	OTTERSON et al., "CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine," Oncogene 11:1211-1216 (1995).	
	/F.L./	258.	Pierce Chemical Company catalog, technical section on cross-linkers, pp. 155-200 (1994).	
	000000000000000000000000000000000000000		RAZIN and GEDAR, "DNA Methylation and embryogenesis," Exc. 64:343-357. **	***************************************
	/F.L./	260.	RAZIN, "CpG methylation, chromatin structure and gene silencing-a three-way connection," EMBO J. 17:4905-4908 (1998).	
	/F.L./	261.	REIK et al., "Epigenetic reprogramming in mammalian development." <u>Science</u> 293:1089-1093 (2001).	
	/F.L./	262.	ROTH, "Bringing out the best features of expression data," Genome Res. 11:1801-1802 (2001).	
		263	SAMBROOK et al. Molecular Cloning: A Laboratory Manual. 2d Ed. Cold Spring	000000000000000000000000000000000000000
			Harbor Laboratory Press, Cold Spring Harbor, NY (1989).	
		264.	SASAKI, ALLEN AND SURANI, "DNA methylation and genomic imprinting in mammals," Exs. 64, 469-486. (1993). **	00000000000000000
	/F.L./	265.	SCHAFER et al., "DNA variation and the future of human genetics," Nature Biotechnology 16:33-39 (1998).	
000000	000000000000000000000000000000000000000	-266	SCHULZ, "DNA methylation in urological malignancies (review)," Int. J. Oncol. 13:151	00000000000000000
	~	ĺ	167.**	
	/F.L./	267.	SINGER-SAM et al., "A quantitative HpaII-PCR assay to measure methylation of DNA from a small number of cells," <u>Nucleic Acids Res.</u> 18:687 (1990).	,
	/F.L./	268.	TAYLOR et al., "The diagnostic significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders," <u>Leukemia</u> 15:583-589 (2001).	
		269.	TIJSSEN, Techniques in Biochemistry and Molecular Biology—Hybridization with	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Nucleic Acid Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays", Elsevier Publishing, New York (1993). **	
	***************************************	270.	WANG et al., "Large-scale identification, mapping, and genotyping of single-nucleotide	*****
			polymorphisms in the human genome," <u>Science</u> 280:1077-1082 (1998).	
	/F.L./ ·	271.	WHITCOMBE et al., "Detection of PCR products using self-probing amplicons and fluorescence," Nature Biotechnology 17:804-807 (1999).	
u		•	<u> </u>	

EXAMINER /Example Little	DATE CONSIDERED
/Frank Lu/	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This references is not a way and a larger of the second of t

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 067234-0130	SERIAL NO. 10/537,204	
	APPLICANT FAN, Jian-Bing		
(PTO-1449)	FILING DATE	GROUP 1634	

/F.L./	272.	YAN, et al., "Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer," J. Mammary Gland Biol. Neoplasia, 6:183-192 (2001).	
/F.L./	273.	ZHONG et al., "A survey of FRAXE allele sizes in three populations," Am. J. Med. Genet. 64:415-419 (1996).	

EXAMINER	DATE CONSIDERED
/Frank Lu/	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference is not attached. Will be provided under separate cover.